Funding Opportunity PAR-21-123 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Funding Opportunity PAR-21-124 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Pension, bonus, healthcare: Paramount Recruitment: FAIR Data Manager - Germany We are working exclusively with a client who develop breakthrough therapies and innovative health care solutions in Baden-Württemberg, Germany

Competitive Salary: EMBL: About this position We are looking for a Team Administrator to join the Research Office at the European Bioinformatics Institute (EMBL-EBI) located Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: About this position We are looking for a Grants Officer to join us at the European Molecular Biology Laboratory – European Bioinformatics Institute Hinxton, Cambridgeshire, England

Funding Opportunity PAR-21-190 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Notice NOT-NS-21-039 from the NIH Guide for Grants and Contracts

(4) Laboratory expertise with nucleic acid microarrays, next gen sequencing, bioinformatics, and data analysis is a plus; Social distancing guidelines in place. $20 - $30 an hour
From Indeed - Thu, 11 Mar 2021 22:29:46 GMT - View all Madison, WI jobs

Notice NOT-AR-21-019 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-033 from the NIH Guide for Grants and Contracts

GBP35000 - GBP48000 per annum: Paramount Recruitment: Bioinformatics Post-Doc- Pipeline Developer Cambridge This is a great opportunity for a Bioinformatics/Comp Bio/Data Science/Statistical Genetics Cambridge, England

Notice NOT-MH-21-210 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MD-21-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to conduct innovative research supporting the development of a product, tool, technology, process or service for commercialization with the aim of eliminating disparities in socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minority populations or improving health in racial/ethnic minority populations.

Funding Opportunity RFA-MD-21-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations experiencing health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.

Funding Opportunity PA-21-202 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ), in partnership with the Patient-Centered Outcomes Research Institute (PCORI), invites applications for funding to support innovative patient-centered outcomes research small pilot projects in Learning Health Systems (LHS) that evaluate the outcomes of embedded research and evaluate the processes by which embedded research can enhance impact, stakeholder engagement, and other health system-identified outcomes of interest.

Funding Opportunity RFA-NS-21-015 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered.

Funding Opportunity RFA-NS-21-016 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

Funding Opportunity PAR-21-163 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

“Working from home, I feel unable to control whether my children are visible,” this professor writes

Notice NOT-MH-21-190 from the NIH Guide for Grants and Contracts